Literature DB >> 10702722

New advances in the diagnosis of congenital cytomegalovirus infection.

T Lazzarotto1, S Varani, L Gabrielli, P Spezzacatena, M P Landini.   

Abstract

With the advances in anticytomegalovirus (anti-CMV) serology, the new recombinant IgM tests seem likely to become the screening tests for pregnant women whose prepregnancy serological status for CMV is unknown. When a woman is found to be IgM-positive, further diagnostic evaluation focused on determining whether this is due to a primary infection should be carried out. Maternal primary infections that were difficult to determine until a few years ago unless documented by seroconversion can now be readily diagnosed from the presence of low-avidity anti-CMV antibody which persists for approximately 20 weeks after primary infection. In primarily infected mothers prenatal diagnosis can be performed between 21 and 23 weeks of gestation, and the amniotic fluid (AF) represents the pathological material of choice to determine intrauterine virus transmission. In AF, the virus can be detected by culture and/or PCR. Both procedures differentiate uninfected from infected fetuses, but cannot predict fetal outcome. The determination of the viral load in AF carried out by quantitative PCR is more promising and could represent an important starting point for preemptive fetal therapy. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10702722     DOI: 10.1159/000053976

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  10 in total

1.  Screening of congenital cytomegalovirus infection by real-time PCR in urine pools.

Authors:  Paulo Paixão; Sofia Almeida; Paula A Videira; Dário Ligeiro; Teresa Marques
Journal:  Eur J Pediatr       Date:  2011-05-26       Impact factor: 3.183

2.  Cytomegalovirus infection in pregnancy: review of the literature.

Authors:  Silvia Bonalumi; Angelica Trapanese; Angelo Santamaria; Laura D'Emidio; Luisa Mobili
Journal:  J Prenat Med       Date:  2011-01

3.  Diagnosis of and screening for cytomegalovirus infection in pregnant women.

Authors:  S C Munro; B Hall; L R Whybin; L Leader; P Robertson; G T Maine; W D Rawlinson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples from mothers with primary infection.

Authors:  S Gouarin; E Gault; A Vabret; D Cointe; F Rozenberg; L Grangeot-Keros; P Barjot; A Garbarg-Chenon; P Lebon; F Freymuth
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

5.  Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers.

Authors:  D Lang; R Vornhagen; M Rothe; W Hinderer; H H Sonneborn; B Plachter
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

6.  Nested polymerase chain reaction in the diagnosis of congenital cytomegalovirus infection.

Authors:  R Sivakumar; N Singh; S Singh
Journal:  Indian J Pediatr       Date:  2001-11       Impact factor: 1.967

7.  Cloning, molecular characterization of a 13-kDa antigen from Schistosoma japonicum, Sj13, a putative salivary diagnosis candidate for Schistosomiasis japonica.

Authors:  Yan-ping Zhou; Zhong-dao Wu; Lin-lin Yang; Xi Sun; Xu You; Xin-bing Yu; Wei Hu; Huan-qin Zheng; Zhi-yue Lv
Journal:  Parasitol Res       Date:  2009-07-29       Impact factor: 2.289

Review 8.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

9.  Congenital Cytomegalovirus Infection.

Authors:  James F. Bale; Lonnie Miner; Susan J. Petheram
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

10.  Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel.

Authors:  Galia Rahav; Rinat Gabbay; Asher Ornoy; Svetlana Shechtman; Judith Arnon; Orna Diav-Citrin
Journal:  Emerg Infect Dis       Date:  2007-11       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.